![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 3, 1557-1564, January 21, 2000
From the Institut für Medizinische Biochemie und
Molekularbiologie, Universitäts-Krankenhaus Eppendorf,
Martinistrasse 52, D-20246 Hamburg, the § Institut für
Medizinische Strahlenkunde und Zellforschung, Universität
Würzburg, Versbacher Strasse 5, D-97078 Würzburg,
¶ Brahms Diagnostica, Komturstrasse 19-20, D-12099 Berlin, and
the A segment of inositol 1,4,5-trisphosphate
3-kinase responsible for inositol 1,4,5-trisphosphate
(InsP3) binding was characterized and confirmed by
three different approaches employing the fully active expressed
catalytic domain of the enzyme. Part of this moiety was protected from
limited tryptic proteolysis by InsP3. Sequencing of two
fragments of 16 and 21 kDa, generated in the absence or presence of
InsP3, respectively, identified segment Glu-271 to Arg-305
as being protected. 15 monoclonal antibodies, all binding to epitopes
within this region, inhibited enzyme activity and interfered with
inositol phosphate binding. Detailed enzyme kinetic parameters of 32 site-directed mutants revealed residues Arg-276 and Lys-303 in this
segment and Arg-322, located nearby, as directly involved in and five
other closely neighbored residues, all located within a segment of 73 amino acids, as also influencing InsP3 binding. Part of
this region is similar in sequence to an InsP3 binding
segment in InsP3 receptors. Combined with the finding that
mutants influencing only ATP binding all lie outside this region, these
data indicate that an InsP3 binding core domain is inserted
between two segments acting together in ATP binding and phosphate transfer.
The second messenger inositol 1,4,5-trisphosphate
(InsP3)1 is
phosphorylated by a 3-kinase to inositol 1,3,4,5-tetrakisphosphate (InsP4). Recently this product has received attention
because of a growing number of discovered biological functions such as regulation of GTPase-activating proteins (1) and vesicle
formation/fusion by adapter protein binding (for review, see Refs. 2
and 3). Inositol 1,4,5-trisphosphate 3-kinase (IP3K) is one of the few enzymes that bind InsP3 with high affinity and high
selectivity. How this combination of affinity and selectivity is
achieved by InsP3-binding proteins is largely unknown to
date, as are the structural requirements for highly selective
InsP3 binding.
The most prominent InsP3-binding protein is the
InsP3 receptor (IP3R), a tetrameric Ca2+
channel residing in the endoplasmic reticulum, of which three isoenyzmes, types I-III, have been characterized on the cDNA level (4-6) (for review, see Ref. 7). For the IP3R the InsP3
binding domain has been confined to the amino-terminal 580 amino acids, with a minimal binding moiety of 353 amino acids (amino acids 226-578), displaying somewhat reduced affinity for InsP3
(8). Particularly, three conserved basic amino acids have been pointed out by site-directed mutagenesis as being involved in ligand binding (8). Furthermore, photoaffinity labeling with InsP3 analogs identified a peptide comprising amino acids 476-501 of the IP3R as
being part of the InsP3 binding site (9).
Besides the IP3R some members of a family of inositol
polyphosphate/inositol phospholipid 5-phosphatases are also capable of
binding to InsP3 with high affinity (for review, see Refs. 10 and 11). An InsP3 binding segment has been located in
the catalytic domain of type II inositol polyphosphate 5-phosphatases, with two short, highly conserved amino acid motifs
(WXGDXNXR and
PXWCDRXL) identified by mutational analysis as
being involved in catalysis and/or substrate binding (12). Particularly
the arginine residue (Arg-480; bold above) was found to increase the enzyme's Km for InsP3, reflecting a
reduced affinity for InsP3 (12).
Two further proteins, which do not metabolize InsP3, have
been found to bind it by experiments using photoaffinity analogs and
specific affinity purification (13). One of these proteins was
identified by peptide sequencing as phospholipase C IP3K is known as a highly selective InsP3-binding protein
(16) with high affinity for this substrate, as illustrated by Km values ranging from 0.7 to 3.1 µM
(17-21) depending on the source and isoform examined. Several
cDNAs for this enzyme have been cloned, e.g. three
different isoforms, designated A The catalytic domain of the enzyme has been mapped to the C terminus
with the last 275 amino acids being indispensable for enzyme activity
(28). This domain also shows the highest degree of amino acid
conservation (30% identities) between isoforms and between species.
Within this region Lys-197 and Asp-414 have been found to be involved
in ATP binding in rat isoform A by site-directed mutagenesis (29). A
recent study has gathered evidence for the involvement of one lysine
residue (Lys-262) in rat isoform A (30) in InsP3 binding.
Here we demonstrate that in the chicken IP3K A-isoform a 35-amino acid
region (amino acids 271-305) is protected against tryptic cleavage
after InsP3 binding and that monoclonal antibodies
recognizing epitopes within this region have inhibitory effects on the
enzyme activity and interfere with InsP4 binding to the
enzyme. Moreover, the enzymatic properties of recombinantly expressed
mutant proteins clearly indicate the direct involvement in
InsP3 binding of three residues (Arg-276 and Lys-303)
within or close to this region (Arg-322) and a participation in binding
of five neighbored residues, all lying within a 73-amino acid segment,
centered in the catalytic domain.
Cloning, Expression, and Purification of a GST-IP3K Fusion
Protein--
A bacterial expression vector, designated pGEX-SE1, was
constructed by ligation of a 570-base pair fragment from a polymerase chain reaction product (polymerase chain reactions 5 and 4 (21)), comprising amino acids 164-351 of chicken IP3K, into vector pGEX2T (Amersham Pharmacia Biotech, Freiburg). XL1 Blue bacteria transformed with pGEX-SE1 according to Ref. 31 were used for overexpression of the
GST-IP3K fusion protein (Pharmacia GST fusion kit). After 2 h of
induction of protein expression by 0.1 mM
isopropyl-1-thio- Generation of Monoclonal Antibodies against a GST-IP3K Fusion
Protein--
Monoclonal antibodies were produced according to the
technique in Ref. 32. A BALB/c mouse was injected on day 0 and day 15 intraperitoneally and subcutaneously with 10 µg of affinity-purified GST-IP3K fusion protein in complete and incomplete Freund's adjuvant, respectively. 53 days later the mouse was boosted with 100 µg of
GST-IP3K fusion protein and 200 µg of double-stranded RNA
intravenously and intraperitoneally. 3 days after the boost the
splenocytes were fused with SP2/O myeloma cells.
Generation of COOH-terminal Truncated GST-IP3K Fusion Proteins
for Epitope Mapping of Monoclonal Antibodies--
Plasmid pGEX-SE1 was
modified for nested deletion of the IP3K coding fragment from its
3'-end by cleavage with AccI and TthIII and
insertion of a double-stranded DNA fragment created from the complementary oligonucleotides ND1
(5'-CTCTAGAAAAGGTACCTGACTGACTGAACGT-3') and ND2
(5'-TCAGTCAGTCAGGTACCTTTTCTAGA-3') into the gap. The resulting plasmid
pGEX-SE570 was cleaved with KpnI and XbaI and
then subjected to a nested deletion reaction using the nested deletion
kit of Amersham Pharmacia Biotech. The reaction products were used to transform competent XL1 Blue cells (Stratagene), and the resulting transformants were screened by plasmid minipreparation and restriction enzyme digest for the length of the IP3K coding region. Several truncated plasmids were selected and dideoxynucleotide sequenced (33)
using an Applied Biosystems 377 automated Sequenator. Bacterial colonies harboring plasmids of interest were then cultured and induced
for the expression of GST fusion proteins as described above. Lysates,
prepared as described above, were directly used for SDS-PAGE and
Western blotting.
Production of the Recombinant IP3K and Mutants in Escherichia
coli--
A 306-amino acid fragment of chicken comprising CaM binding
and catalytic domain, designated IP3K147-C, as well as the
derived mutant proteins were overexpressed in E. coli
BL21(DE3) bacteria transformed with plasmid pEGIK or mutated derivates
thereof and purified on phosphocellulose and CaM-Sepharose as described
(21).
Partial Proteolytic Cleavage of Recombinant IP3K--
For a time
course of proteolysis, affinity-purified IP3K147-C at a
concentration of 0.48 mg/ml was digested in a 50-µl volume at
30 °C in 50 mM sodium phosphate buffer, pH 7.8, with
0.01 mg/ml trypsin (sequencing grade) for up to 20 min. Trypsin was
added from a 0.5 mg/ml stock solution in 1 mM HCl, and
10-µl samples were withdrawn from the reaction and stopped by mixing
with 3.3 µl 4 × SDS-PAGE sample buffer (0.2 M
Tris-Cl, pH 6.8, 15% glycerol, 8.6% SDS, 0.8 M
mercaptoethanol, 0.4 mg/ml bromphenol blue) and immediate heating to
95 °C for 8 min. For experiments regarding the effects of substrates
on proteolysis, either 1 mM ATP or 250 µM
InsP3 or both were added to the same reaction buffer. The
dependence of proteolysis on the InsP3 concentration was
determined in parallel reactions (10 µl) containing 50 mM
Tris-Cl, pH 7.5, 0.24 mg/ml IP3K, 0.01 mg/ml trypsin, and
InsP3 varying from 0.5 to 100 µM. After 20 min the reaction was stopped as above. For the determination of
NH2-terminal peptide sequences of proteolysis
intermediates, samples separated by SDS-PAGE were blotted to
polyvinylidene difluoride membranes (34), and immobilized protein bands
were sequenced on an Applied Biosystems 470 A Sequenator.
Site-directed Mutagenesis of IP3K Catalytic Domain--
The
mutagenesis of the catalytic domain of chicken IP3K was done
essentially as described in Ref. 35. Either plasmid pEGIK (21) or
plasmid pGEM-IP3K Xba/Sph, based on the vector pGEM3Z (Amersham
Pharmacia Biotech) and containing a 460-base pair insert of chicken
IP3K representing amino acids 147-299, was used as template. For the
pGEM-IP3K Xba/Sph template, primers NP24
(5'-GACGTTGTAAAACGACGGCCAGTG-3') and RP24
(5'-AACAGCTATGACCATGATTACGCC-3') were used as flanking primers, whereas
for the pEGIK template primers UB24
(5'-GAAGAGCTCACTGAAGCCCGTGAGAAACC-3') and UB40
(5'-CTGAGTGATCTCTCTAGAGAAGAAAGTTAGTTA-3') were used as flanking
primers. All oligonucleotides were from MWG Biotech (Ebersberg, Germany). The resulting polymerase chain reaction products were ligated
into appropriately digested plasmid vectors. E. coli XL1 Blue cells transformed with the ligation products were selected for
positive transformants by plasmid minipreparation and restriction digests. Insert sequences were verified by dideoxynucleotide
sequencing. Appropriate restriction fragments of mutated polymerase
chain reaction products were ligated into plasmid pEGIK. For the
expression of mutant proteins BL21(DE3) bacteria were transformed with
these vectors.
Optical Enzyme Assay for Determination of Specific IP3K Activity
and Km Values for Substrates of Recombinant IP3K and
Mutants--
IP3K activity and the Km values for
InsP3 were determined as described previously (21). The
Km values for ATP were derived from initial rates
with a saturating initial InsP3 concentration of 25 µM and varying initial concentrations of ATP (0.025-2
mM). Statistic testing was with t test for
unpaired samples.
Western Blotting--
SDS-PAGE was done according to Ref. 36.
Semidry Western blotting was performed essentially as described (34).
For the simultaneous detection of immunoreactivity of all monoclonal
antibodies against fragments of IP3K, a whole SDS-polyacrylamide gel
was loaded with protein in a pocket covering the entire width of the gel. After blotting, the membranes were fixed in a multiwell chamber (Phase, Lübeck, Germany) allowing the simultaneous application of
up to 20 primary antibody solutions for immunodecoration onto separate,
sealed strips of the membrane, with each strip covering the entire
separation length of the gel in the running direction. After incubation
with primary antibodies on separate membrane strips, the membrane was
treated as a whole with secondary antibody, washing, and staining solutions.
InsP3 Protects a 35-Amino Acid Fragment of IP3K from
Limited Proteolysis--
We subjected the recombinantly expressed
catalytic domain of chicken IP3K147-C to a limited protease
treatment in the absence or presence of ATP and InsP3 and
analyzed the resulting proteolytic fragments on SDS-PAGE. In the
absence of substrates, cleavage with trypsin resulted in the immediate
formation of at least five distinct bands with slightly reduced
apparent molecular masses (36-32 kDa) down to a more
protease-resistant fragment of 31 kDa (Fig.
1A). The most prominent stable
cleavage intermediate of lower molecular mass was a 16-kDa fragment
that was formed shortly after the 31-kDa fragment. The same cleavage
pattern was found if ATP was present in the reaction mix at a
concentration of 1 mM (not shown). In contrast, the
presence of 250 µM InsP3 led to the formation
of a quite stable, prominent 21-kDa digestion intermediate, whereas the
formation of the 16-kDa fragment was suppressed (Fig. 1B).
Besides, a stabilization of a 31-kDa fragment occurred also. The same
pattern of proteolytic fragments was observed when both substrates ATP
(1 mM) and InsP3 (250 µM) were
present (not shown). Amino-terminal peptide sequences of isolated
proteolytic fragments were determined (Fig.
2). For the 31-kDa band two superimposed sequences with initial yields of 70 and 49 pmol, respectively, were
found, which could be easily assigned to two fragments starting at
Tyr-178 and Ala-191, respectively. The 21-kDa band yielded a single
peptide sequence (initial yield 159 pmol) corresponding to a fragment
starting at Glu-271. Two superimposed sequences were also found for the
16-kDa band, which could be attributed to two fragments starting at
Tyr-306 and Glu-311 with initial yields of 78 and 63 pmol,
respectively. The observed Mr values imply that
all fragments are not or only minimally truncated at the COOH terminus
of the catalytic domain. Therefore, a segment protected from cleavage
by trypsin in the InsP3-bound state (i.e. the
NH2-terminal part of the 21-kDa fragment which is not
present in the 16-kDa band) comprises 35 amino acids ranging from
Glu-271 to Arg-305 (Fig. 3). Using
varying InsP3 concentrations during tryptic digestion, an
EC50 value of 36 µM was derived for the inhibition of tryptic cleavage after residues Arg-305 and Arg-310 as
detected by the percentage of 21-kDa fragment formed. An even lower
EC50 value (2.6 µM) was found for the
inhibition of cleavage after residue Arg-270 related to the percentage
of 31-kDa band formation (Fig. 4).
Monoclonal Antibodies Specific for Chicken IP3K Bind to Epitopes
within the "InsP3-protected" Region and Show Partial
Inhibitory Effect on IP3K Activity--
For 15 monoclonal mouse
antibodies, generated against an IP3K fragment ranging from Thr-164 to
Val-341 and designated Kin3-Kin17, the epitope location and their
effect on enzyme activity were investigated. Western blot experiments
with a set of NH2-terminally or COOH-terminally truncated
IP3K fragments, generated either by tryptic digestion of
IP3K147-C or by nested deletion of the coding sequence for
a GST-IP3K fusion protein (see "Experimental Procedures"), revealed
for all monoclonal antibodies only epitopes within the 35-amino acid
segment protected by InsP3 against tryptic cleavage. All
antibodies recognized the NH2-terminally truncated 21-kDa
fragment starting at Glu-271 (Fig.
5B) and none the 16 kDa
fragment starting at Tyr-306 (Fig. 5A). On the other hand, the COOH-terminally truncated fragment from Thr-164 to Glu-285 was
recognized extremely weakly only by antibodies Kin4, -6, -9, and -17 (Fig. 5E). The fragment from Thr-164 to Leu-289, four amino
acids longer, was recognized strongly by six antibodies (Kin4, -6, -9, -13, -15, and -17; Fig. 5D), whereas all antibodies reacted
with the fragment from Thr-164 to Ala-317(Fig. 5C). The weak
lower Mr bands appearing in Fig. 5E
in the lanes of the antibodies Kin8, -11, -12, and -13 appear to be
caused by cross-reactivity toward unrelated E. coli
proteins, which are more prominent on this particular blot, since the
staining sensitivity was enhanced in order to detect the weak specific
reactivity toward the IP3K fusion protein. From this pattern of
immunoreactivity we can conclude that the motif "VDPL" (position
286-289) is part of the epitopes recognized by six of the monoclonal
antibodies and that their complete epitopes (epitope A) lie between
Glu-271 and Leu-289. The epitope recognized by all other antibodies
(epitope B) is contained within the segment from Ala-290 to Arg-305. A
schematic representation is shown in Fig. 3.
In enzyme assays performed with IP3K147-C under
Vmax conditions for both substrates in the
presence and absence of antibodies, all antibodies inhibited IP3K
activity by at least 30% and up to 70% when they were present at a
molar ratios of 0.7 to 3, antibody binding sites to IP3K (Fig.
6). In all cases the observed inhibition clearly exceeded the inhibition of 11% measured in control reactions with a nonspecific antibody. To clarify the mechanism by which the
antibodies exert their inhibitory effects on IP3K, two of the strongest
binding antibodies (Kin4 binding to epitope A and Kin8 binding to
epitope B) were selected for a determination of their effect on the
Km values of IP3K. No direct effects on the
Km values (derived from single transients, see Ref.
21) for InsP3 (Fig.
7A for Kin4, Fig.
7B for Kin8) and Km values for ATP (data
not shown) were found but only Vmax effects.
However, in experiments in which InsP4, acting as a
competitive product inhibitor for InsP3, was included from
the beginning at a concentration of 5 µM, Kin4 showed a
synergistic effect with InsP4 in increasing the
Km value for InsP3 (Fig. 7A),
whereas Kin8 partially antagonized the effect of InsP4 on
the Km value for InsP3 (Fig.
7B).
Amino Acids within the Region Protected from Proteolysis by
InsP3 Contribute to InsP3 Binding--
To
elucidate the role of individual amino acids in the cleavage protected
region more thoroughly, we introduced several point mutations into this
part and the neighboring segments of the protein. Most of these mutated
residues are shown in Fig. 3. The mutant enzyme forms were bacterially
expressed as IP3K147-C fragments, purified to about 70%
homogeneity on phosphocellulose. Most were additionally affinity
purified by CaM-Sepharose affinity chromatography (to >98%
homogeneity) and then subjected to a detailed analysis of specific
activity and Km values for both substrates. From 32 mutations generated, three (double mutant D240A/D241A, C254S, and
R259N) obviously displayed aberrant folding behavior because the mutant
proteins became entirely insoluble and therefore could not be studied
further. Among the remaining 29 mutants, 12 turned out to have no
significantly altered enzymatic properties compared with the wild-type
enzyme. Three mutants, designed to reproduce previously described
enzymatic knock-out mutants of rat IP3K isoform A (29, 30), also
resulted in completely inactive enzymes (K255A, K255N, and D407S).
Therefore, also in avian IP3K-A, Lys-255, (corresponding to Lys-262 in
rat isoform A) and Asp-407 (corresponds to Asp-414 in rat isoform A)
are indispensable for catalysis. However, a conservative substitution
at the critical residue Lys-255 (K255R) displayed no enzymatic
alterations against the wild-type (Fig.
8A-D), demonstrating
that only a positively charged amino acid is essential at this
particular position.
With respect to ATP binding, five novel mutants (K176L, D245A, E247L,
K327Q, and the double mutant D245A/E247L) showed significant elevations
of the Km for ATP ranging from 1.6- to 2.1-fold (Fig. 8D), whereas their Km values for
InsP3 remained nearly unchanged. These residues either lie
between 23 and 94 amino acids upstream or 22 residues downstream of the
protein region that is protected by InsP3 from proteolysis.
InsP3 binding was altered significantly in 10 mutants
regarding eight residues (Fig. 8A), four of which (Lys-274,
Arg-276, Lys-277, and Lys-303) lie within the
InsP3-protected region, whereas two (Thr-267 and Arg-270)
lie only four and one residue, respectively, upstream of the tryptic
cleavage site in the InsP3-bound state of IP3K. The
remaining two residues Arg-322 and Lys-327, on the other hand, lie 17 and 22 amino acids downstream of the InsP3-protected region.
The Km values for InsP3 of the mutants
R276L, K303Q, and R322L display highly significant 11-, 16-, and
15-fold increases, respectively, compared with wild-type IP3K. Even the
R276K and R322K mutations, which retain a positive charge at the
respective positions, still have significantly (2.3-fold and 8.4-fold)
increased Km values for InsP3. Although
the maximal catalytic activities of mutants R276L and R276K equal or
rather exceed that of the wild-type protein (Fig. 8C),
mutants K303Q, as well as R322K, and R322L, display strongly impaired
catalytic activity, with 3.8-33-fold lower Vmax
values (all exhibiting p < 0.001) than wild-type (Fig.
8C). In particular, the conservative substitution in R322K,
resulting in a 28-fold lower specific activity, indicates a strict
requirement for arginine at this particular position for
InsP3 binding and efficient catalysis.
Although not as evident as the above loss of function mutations, the
Km values for InsP3 of five other
mutants turned out to be equally interesting because they unexpectedly
exhibited lower Km values for InsP3
(indicative of better substrate binding) than the wild-type. The mean
apparent Km of these mutants for InsP3
is in all cases significantly (p < 0.005) reduced
about 2-fold to between 0.3 and 0.35 µM compared with 0.69 µM for the wild-type. The increased apparent
affinity of these mutants for InsP3 is also reflected (with
the exception of K327Q) in their increased specific activities (Fig.
8C) and in their increased catalytic processivities
(kcat), derived from Vmax/Km (Fig.
8B).
A 35-amino acid region almost in the middle of the 275-mino acid
catalytic domain of chicken IP3K is protected from proteolysis in the
InsP3-ligated enzyme. Apparently this segment of the enzyme containing the basic residues recognized by trypsin in the absence of
InsP3 undergoes some major structural rearrangement upon
InsP3 binding. The absence of large fragments derived from
polypeptide Ala-191 to Arg-270 suggests an unfolding and further
multiple cleavage of this segment when released. Whereas Arg-270, the
cleavage site in front of the 21-kDa fragment and other more
NH2-terminal sites, may always be exposed to proteolytic
attack, Arg-305 and Arg-310 clearly become "protease-protected" in
the presence of InsP3. Such protection implies that some of
the residues within the protected region must be more or less directly
involved in binding of InsP3 to the enzyme. The affinities
of the proteolytic fragments for InsP3 can be inferred
approximately from their EC50 values for protection against
trytic attack. Whereas that for the 31-kDa band is only about 4-fold
above the Km value for InsP3, that of
the 21-kDa fragment is about 50-fold higher than Km.
This means that although most of the structural components necessary
for InsP3 ligation may be contained within the 21-kDa
fragment, some residues within the upstream segment from Ala-191 to
Arg-270 must also participate in InsP3 binding. For one
residue, namely Lys-255, this has been directly proven by our
mutational analysis. The participation of residues upstream of Lys-255
was made unlikely by previous studies (30).
The significant inhibitory effects of all antibodies binding to
epitopes directly downstream of Arg-270 on the catalytic activity of
IP3K could be the result of (i) a direct blocking or displacement of
residues involved in catalysis, (ii) steric hindrance of the entry of
substrates, or (iii) a general conformational inactivation of the
enzyme. In the first two cases this would imply the direct participation of epitope-forming residues in InsP3 binding
or their close proximity to the binding pocket. However, the inhibitory effect of the antibodies could not be attributed directly to an interference with InsP3 binding because no significant
changes in the Km value for InsP3 were
found in presence of selected strong inhibitory antibodies. Still, the
observed interference of both subtypes of antibodies with binding of
InsP4, exemplified with Kin4 and Kin8 indicates that their
epitopes in either case may overlap with the
InsP3/InsP4 substrate/product binding site and
may constitute that part of the enzyme which interacts with the
additional phosphate group of InsP4.
By mutational substitution of positively charged residues within the
protease-protected region and the antibody epitopes we confirmed that
Arg-276 and Lys-303 participate directly in InsP3 binding
but not in ATP binding. How these basic residues interact with
individual phosphates of substrate or product is clarified in ongoing
substrate selectivity studies. A further indication that this segment
of IP3K is mainly involved in inositol phosphate binding is the fact
that seven other mutations within or close to this region also show
effects on Km for InsP3 and therefore on
InsP3 binding to the active site. The intriguing observation that five of these replacements promote rather than inhibit
InsP3 binding needs to be clarified by three-dimensional structure determinations. As indicated by their increased
kcat values, these mutants indeed represent
artificially optimized versions of IP3K concerning catalytic
processivity. It will be interesting to learn what has prevented the
natural enzyme from evolving toward these forms.
Our results also support and complement previous findings that showed
that Lys-262 in rat IP3K isoform A, corresponding to Lys-255 in our
IP3K, is essential for catalysis and InsP3 binding (30).
Our nonconservative mutations in this position did also abolish
catalytic activity in chicken IP3K, whereas the conservative one did
not (see "Results"). All of our additional mutations affecting InsP3 binding lie closely downstream of this apparent
starting point of the InsP3 binding segment, identified by
an NH2-terminal deletion of the rat isoform, corresponding
to Leu-252 in our enzyme. We have now identified a total of eight amino
acids involved in InsP3 binding, within a 73-amino acid
segment from Lys-255 to Lys-327, covering also the segment protected by
InsP3 binding against tryptic cleavage and the antibody
epitopes (see Fig. 3).
Our studies also discovered the hitherto unknown participation in ATP
binding of four residues (Lys-176, Asp-245, Glu-247, and Lys-327),
which are all located outside this segment. Taken together with the
residues described previously as being essential in ATP binding (29) it
thus appears that two ATP binding segments, making up the
NH2- and COOH-terminal ends of the catalytic domain, are
flanking a central segment involved in InsP3 binding. In a previous study (30) short COOH-terminal truncations by up to nine amino
acids led to an almost complete (1/3800) loss of enzyme activity,
whereas InsP3 binding was only reduced by about 1 order of
magnitude. This indicates that either enzyme activity or ATP binding
depends strongly on the presence of a most likely helical intact COOH
terminus. The much weaker influence of these truncations on
InsP3 binding than on catalytic activity may be indicative of a more indirect facilitative, e.g. conformational,
involvement of the COOH terminus in InsP3 binding and thus
does not contradict the model of an InsP3 binding core segment.
The part of this segment encompassing residues 259-284 shows a distant
similarity to a segment of the IP3R (24) (Fig.
9) containing four residues involved in
InsP3 binding (8). In fact, the exchange of Arg-276 in IP3K
and of the corresponding arginine residue in the IP3R has the same
consequence: the reduction of InsP3 affinity (Fig. 9).
Also, the mutation of Lys-268 in IP3K and of corresponding Lys-501 in
IP3R has the same effect, namely no alteration of InsP3
affinity. The main differences regarding the effects of mutations are
found for residues Arg-270, Lys-272, and Lys-274 of IP3K, which
correspond to residues Arg-504, Arg-506, and Lys-508 of IP3R. Exchanges
of these residues in IP3R reduce InsP3 affinity, whereas in
IP3K they do not or even enhance it. Some differences between IP3K and
IP3R regarding the mechanism of InsP3 binding are not
unexpected because the enzymatic activity of IP3K, unlike IP3R, also
requires an efficient release of the product InsP4.
Nevertheless the partial correspondence of critical residues may
reflect the existence of a type of InsP3 binding "core
motif" common to IP3R and IP3K. Whether both are evolutionarily linked or a remarkable case of convergent evolution remains to be
revealed by future genomic analysis.
An intriguing recent observation even allowing further molecular
dissection of this kinase into functional segments comes from a
comparison of the recently identified sequences of InsP6 kinases (37, 38) with those of InsP3 kinases. The most
conserved sequence between these inositol phosphate kinases is a short
segment ranging from Pro-249 to Arg-259 in our IP3K (Fig. 3). This
segment is in immediate continuity with the InsP3 binding
core segment identified in this study. Comparing the latter segment
between InsP3 and InsP6 kinases reveals only a
minor degree of homology, which is not unexpected because of the
differences between the two substrates InsP3 and
InsP6. We therefore propose that the closely neighboring
segment P-C-(VAI)-(ML)-D-X-K-(ML)-G has a common function in
both inositol phosphate kinases, which may be the catalytic phosphate
transfer from ATP to the inositol ring or the positioning of the ATP
We are grateful to Sigrid Poll for excellent
technical assistance as well as to Dr. Gerhard Müller-Newen (RWTH
Aachen, Germany) for help in constructing vector pGEX-SE1. We thank all
students of the molecular biology courses of the Study Course
Biochemistry/Molecular Biology of the University of Hamburg, who have
contributed continuously to mutagenesis and expression of mutant
proteins. In particular we thank students Anne Buschmann, Christian
Buschmann, Ines Krohn, Dennis Pöpplau, and Tonio Wilcek for
substantial contributions. We are indebted to Robin F. Irvine
(University of Cambrigde, U. K.) and Adolfo Saiardi (Johns Hopkins
University, Baltimore, MD) for providing us with manuscripts on
InsP6 kinases before publication.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
Recipient of grants from the Deutsche Forschungsgemeinschaft. To
whom correspondence should be addressed. Tel.: 49-40-42803-4639; Fax:
49-40-42803-6818.
The abbreviations used are:
InsP3, inositol 1,4,5-trisphosphate;
InsP4, inositol
1,3,4,5-tetrakisphosphate;
IP3K, inositol 1,4,5-trisphosphate 3-kinase;
IP3R, inositol 1,4,5-trisphosphate receptor;
GST, glutathione
S-transferase;
DTT, dithiothreitol;
PAGE, polyacrylamide gel
electrophoresis;
CaM, calmodulin;
IP3K147-C, COOH-terminal
fragment (amino acids 147-452) of chicken IP3K.
The Second Messenger Binding Site of Inositol 1,4,5-Trisphosphate
3-Kinase Is Centered in the Catalytic Domain and Related to the
Inositol Trisphosphate Receptor Site*
,
, and
Institut für Klinische Immunologie und
Transfusionsmedizin, Universitätsklinik Leipzig,
Linnéstrasse 3, D-04103 Leipzig, Germany
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1, and the other
one was found to be closely related to phospholipase C
1, although
lacking any detectable phospholipase C activity (14). Only for
phospholipase C
1 the structural requirements for InsP3
binding are already fairly well understood because the pleckstrin
homology domain of this enzyme (amino acids 17-132) has been
identified as the InsP3-binding element, and a crystal structure of this domain bound to InsP3 has been obtained
(15). Within the NH2-terminal part of the pleckstrin
homology domain (amino acids 17-60) five basic, one acidic, and one
aromatic amino acid were identified as being directly involved in
InsP3 binding (15). Two further basic amino acids within
this protein segment were found to be indirectly involved in binding by
site-directed mutation.
C, from human (Refs. 22, 23, and
GenBank accession no. D38169), two isoforms from rat (24-26), and one
isoform from chicken (21). In the nematode worm Caenorhabditis
elegans one gene for IP3K has been identified, which is
alternatively spliced into three different mRNAs (27).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-D-galactopyranoside, the culture was
centrifuged at 5,000 × g for 10 min. The bacterial pellet was resuspended in 1/30 of the culture volume of
phosphate-buffered saline and frozen at
20 °C. The subsequently
thawed bacterial suspension was subjected to lysis by addition of the
following components at the respective final concentrations: 0.5 mg/ml
lysozyme, 0.1 mg/ml DNase I, 0.1% Triton X-100, 1 mM EDTA,
0.1 mM phenylmethylsulfonyl fluoride, 0.5 mM
DTT, and by incubation at 35 °C for 5 min followed by 20 min
on ice. Fusion protein aggregated in inclusion bodies was pelleted by
centrifugation at 10,000 × g for 10 min. The pellet was extracted once with 1/3 of the resuspension volume of detergent buffer (200 mM NaCl, 20 mM Tris-Cl, 2 mM EDTA, 1 mM DTT, 1% deoxycholate, 1%
Nonidet P-40 at pH 7.5) and twice with the same volume of Triton buffer
(20 mM Tris-Cl, 1 mM EDTA, 1 mM
DTT, 0.5% Triton X-100 at pH 7.5) by vigorous vortexing for several
minutes. The extracted pellet was solubilized in 1/3 of the
resuspension volume of 8 M urea in water, centrifuged at
10,000 × g, and the supernatant dialyzed exhaustively
against dialysis buffer (1 × phosphate-buffered saline, 0.5 mM DTT, 0.1 mM phenylmethylsulfonyl fluoride, 1 mM EDTA, 0.1% Triton X-100). Most of the fusion protein
precipitated again during dialysis and was collected by centrifugation
at 10,000 × g. The pellet was solubilized again in 4 ml of 8 M urea and diluted 1:50 with dialysis buffer. The
again dialyzed protein remained soluble and was supplemented with 0.1 mM phenylmethylsulfonyl fluoride, gently mixed with 0.5 ml
of glutathione-Sepharose resin and incubated for 40 min at room
temperature under repeated mixing. The resin was washed on a column
with 3 × 10 ml of dialysis buffer. The bound GST-IP3K fusion
protein was eluted in three 1-ml fractions using elution buffer (50 mM Tris-Cl, 10 mM glutathione, 100 mM NaCl, 0.1 mM phenylmethylsulfonyl fluoride,
1 mM DTT, 1 mM EDTA, 0.1% Triton X-100, pH
7.5). For these steps the resin was kept for 40, 15, and 15 min at room
temperature in elution buffer, respectively.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (40K):
[in a new window]
Fig. 1.
Tryptic digests of recombinant chicken IP3K
in presence and absence of substrates. Coomassie Blue-stained
SDS-polyacrylamide gels loaded with samples from the time course of
digestion with trypsin in the absence of InsP3 and ATP
(panel A), in the presence of 250 µM
InsP3 (panel B) are shown. The duration of
digestion in minutes is given above the corresponding lanes.
Lanes labeled M show molecular mass marker
proteins with molecular masses given in the margin.

View larger version (16K):
[in a new window]
Fig. 2.
NH2-terminal peptide sequences
for proteolytic fragments of IP3K. Amounts of amino acids found
during Edman degradation are shown. Closed and open
circles represent different superimposed sequences, and
corresponding amino acids are indicated by one-letter codes. Assignment
was based on known IP3K sequences. Solid lines represent
fitted linear regressions for the first sequence (closed
circles) and broken lines for the second sequence
(open circles).

View larger version (29K):
[in a new window]
Fig. 3.
Schematic representation of the sequence of
the chicken IP3K fragments used in this study.
Horizontal bars represent (from top):
recombinantly expressed IP3K containing CaM binding and catalytic
domain (first bar), three GST-IP3K fusion proteins generated
by nested deletion (second through fourth bars),
21- and 16-kDa proteolytic fragments (fifth and sixth
bars), and the full-length IP3K from chicken (seventh
bar). The box hatched with vertical lines
represents the NH2-terminal domain in the full-length
protein; horizontal lines are the corresponding segment in
the recombinant protein. The CaM binding domain is represented by a
black box and the catalytic domain by a box with
diagonal hatching. The numbers at the ends of
each fragment denote the amino acid positions. Below, the amino acid
sequence from residue 240 to 329 is given explicitly. The 35 amino
acids protected against proteolysis by InsP3 binding are
boxed. The amino acid segment recognized by most monoclonal
antibodies is represented by a continuous black bar below,
designated Epitope B; the segment recognized by six of the
antibodies is represented by a discontinuous bar, designated
Epitope A. Peptide sequences determined for the 21-kDa and
the 16-kDa fragments are highlighted by gray
background shadings. Amino acids exchanged by site-directed
mutagenesis are indicated by bold characters.
Arrows point to the amino acids that were used for exchange.
Residues, where the mutation affected the steady-state kinetic
parameters of the enzyme, are double underlined, and the
corresponding amino acids used for exchange are underlined.
Mutants leading to aberrant folding are indicated in
italics. The entire InsP3 binding segment
identified is shown by a horizontal two-headed arrow. The
region of homology between InsP3 and InsP6
kinases is boxed with a broken line.

View larger version (41K):
[in a new window]
Fig. 4.
Dependence of the protection against
proteolysis on InsP3 concentration. In panel
A the Coomassie-stained SDS-PAGE analyses of samples from
identical tryptic digests of IP3K at varying InsP3
concentrations are compared. InsP3 concentrations in the
digests are indicated above each lane in µM.
Lane M contains molecular mass marker proteins with
molecular masses indicated in the right margin. Lane
C shows the undigested starting material. In panel B
the percentages of the protected 21- and 31-kDa fragments after digest,
as measured by densitometry, are plotted against the InsP3
concentration.

View larger version (53K):
[in a new window]
Fig. 5.
Epitope characterization of monoclonal
antibodies against chicken IP3K. Proteolytic fragments
(panels A and B) of chicken IP3K and bacterially
produced GST-IP3K fusion proteins in bacterial lysates (panels
C
E) were probed simultaneously with 15 monoclonal
antibodies against chicken IP3K in parallel lanes (see "Experimental
Procedures"). In panel A the immunoreactivity of the
monoclonal antibodies toward NH2-terminally truncated 31- and 16-kDa fragments of chicken IP3K, resulting from a tryptic digest
in the absence of InsP3, is shown; in panel B a
tryptic digest in the presence of 250 µM
InsP3 with defined, NH2-terminally truncated
31- and 21-kDa fragments was used. In panels C-E the
immunoreactivity toward COOH-terminally truncated GST-IP3K fusion
proteins is shown, using crude bacterial lysates containing IP3K
fragments comprising amino acids 164-317 in panel C,
164-289 in panel D, and 164-285 in panel E. The
positions of the expected fragments are indicated in the right
margin; positions and molecular masses of marker proteins are
indicated in the left margin. Lane numbering
corresponds to the number of the respective antibody used to incubate
the membrane strip. FP, GST-IP3K fusion protein. In
panel F, identical amounts of the lysates used in
panels C-E were blotted and incubated with an anti-GST
antibody to ensure the expression of the truncated fusion proteins.
Lane A contains the fragment 164-289; lane B,
fragment 164-317; and lane C, fragment 164-285.

View larger version (14K):
[in a new window]
Fig. 6.
Inhibition of IP3K activity by monoclonal
antibodies. The percentage of inhibition of the IP3K activity by
monoclonal antibodies was determined with enzymatic optical assays (see
"Experimental Procedures") using 2.25-18 nM antibody
and 6.68 nM IP3K (light gray columns). For the
control reaction an anti-GST antibody was used at 4 nM.
Results are means of at least three independent measurements, with S.D.
indicated by error bars.

View larger version (16K):
[in a new window]
Fig. 7.
Influence of selected antibodies on
Km for InsP3 in the presence of
InsP4. Lineweaver-Burke plots are shown for measurements of IP3K
activities with or without 5 µM InsP4 and
with or without 4 nM Kin4 in panel A and Kin8 in
panel B.

View larger version (59K):
[in a new window]
Fig. 8.
Enzymatic parameters of mutant IP3K
proteins. In panel A the Km values
for InsP3 determined for either phosphocellulose-purified
or CaM-Sepharose-purified mutant IP3K proteins are presented. Results
are means of at least three independent measurements, with S.D.
indicated by error bars. Hatched bars indicate
mutants with significantly increased and black bars mutants
with decreased Km values for InsP3. In
panel B the apparent rate constants
(kcat) derived from
Vmax/Km for InsP3
are depicted with their respective error bars. In
panels C and D the specific activities and the
Km values for ATP for CaM-Sepharose-purified mutant
proteins are shown. Mutant proteins only purified by phosphocellulose
chromatography are marked (*). Uninterrupted vertical lines
indicate ± 1 S.D. or error range of the respective wild-type
(WT36kDa) value, respectively. WT32kDa is a proteolytically
shortened form of the recombinant protein, which was also purified by
phosphocellulose chromatography.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (8K):
[in a new window]
Fig. 9.
Sequence comparison of segments in IP3K and
IP3R containing amino acids involved in InsP3 binding.
Homologous residues within the segments are boxed. Residues
that have been mutated are given as bold characters. The
arrows are pointing to the amino acids that have been used
for replacement. The effects of these mutations are indicated either by
bold characters when InsP3 affinity was reduce
or by normal characters when InsP3 binding was
not influenced.
-phosphate close to the acceptor hydroxyl of the inositol ring.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
Recipient of a grant from the Graduiertenkolleg 336 of the
Deutsche Forschungsgemeinschaft.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Cullen, P. J.,
Hsuan, J. J.,
Truong, O.,
Letcher, A. J.,
Jackson, T. R.,
Dawson, A. P.,
and Irvine, R. F.
(1995)
Nature
376,
527-530[CrossRef][Medline]
[Order article via Infotrieve]
2.
Fukuda, M.,
and Mikoshiba, K.
(1997)
BioEssays
19,
593-603[CrossRef][Medline]
[Order article via Infotrieve]
3.
Shears, S. B.
(1998)
Biochim. Biophys. Acta
1436,
49-67[Medline]
[Order article via Infotrieve]
4.
Mignery, G. A.,
Newton, C. L.,
Archer, B. T., III,
and Sudhof, T. C.
(1990)
J. Biol. Chem.
265,
12679-12685 5.
Miyawaki, A.,
Furuichi, T.,
Maeda, N.,
and Mikoshiba, K.
(1990)
Neuron
5,
11-18[CrossRef][Medline]
[Order article via Infotrieve]
6.
Ross, C. A.,
Danoff, S. K.,
Schell, M. J.,
Snyder, S. H.,
and Ullrich, A.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
4265-4269 7.
Berridge, M. J.
(1993)
Nature
361,
315-325[CrossRef][Medline]
[Order article via Infotrieve]
8.
Yoshikawa, F.,
Morita, M.,
Monkawa, T.,
Michikawa, T.,
Furuichi, T.,
and Mikoshiba, K.
(1996)
J. Biol. Chem.
271,
18277-18284 9.
Mourey, R. J.,
Estevez, V. A.,
Marecek, J. F.,
Barrow, R. K.,
Prestwich, G. D.,
and Snyder, S. H.
(1993)
Biochemistry
32,
1719-1726[CrossRef][Medline]
[Order article via Infotrieve]
10.
Woscholski, R.,
and Parker, P.
(1997)
Trends Biochem. Sci.
22,
427-431[CrossRef][Medline]
[Order article via Infotrieve]
11.
Erneux, C.,
Govaerts, C.,
Communi, D.,
and Pesesse, X.
(1998)
Biochim. Biophys. Acta
1436,
185-199[Medline]
[Order article via Infotrieve]
12.
Jefferson, A. B.,
and Majerus, P. W.
(1996)
Biochemisty
35,
7890-7894[CrossRef][Medline]
[Order article via Infotrieve]
13.
Kanematsu, T.,
Takeya, H.,
Watanabe, Y.,
Ozaki, S.,
Yoshida, M.,
Koga, T.,
Iwanaga, S.,
and Hirata, M.
(1992)
J. Biol. Chem.
267,
6518-6525 14.
Kanematsu, T.,
Misumi, Y.,
Watanabe, Y.,
Ozaki, S.,
Koga, T.,
Iwanaga, S.,
Ikehara, Y.,
and Hirata, M.
(1996)
Biochem. J.
313,
319-325
15.
Ferguson, K. M.,
Lemmon, M. A.,
Schlessinger, J.,
and Sigler, P. B.
(1995)
Cell
83,
1037-1046[CrossRef][Medline]
[Order article via Infotrieve]
16.
Irvine, R. F.,
Letcher, A. J.,
Heslop, J. P.,
and Berridge, M. J.
(1986)
Nature
320,
631-634[CrossRef][Medline]
[Order article via Infotrieve]
17.
Ryu, S. H.,
Lee, S. Y.,
Lee, K. Y.,
and Rhee, S. G.
(1987)
FASEB J.
1,
388-393[Abstract]
18.
D'Santos, C.,
Communi, D.,
Ludgate, M.,
Vanweyenberg, V.,
Takazawa, K.,
and Erneux, C.
(1994)
Cell Signal
6,
335-344[CrossRef][Medline]
[Order article via Infotrieve]
19.
Foster, P. S.,
Hogan, S. P.,
Hansbro, P. M.,
O'Brien, R.,
Potter, B. V.,
Ozaki, S.,
and Denborough, M. A.
(1994)
Eur. J. Biochem.
222,
955-964[Medline]
[Order article via Infotrieve]
20.
Shin, Y. S.,
Choi, G.,
and Hoi, K. Y.
(1995)
Molecules Cells
5,
348-353
21.
Bertsch, U.,
Haefs, M.,
Moller, M.,
Deschermeier, C.,
Fanick, W.,
Kitzerow, A.,
Ozaki, S.,
Meyer, H. E.,
and Mayr, G. W.
(1999)
Gene (Amst.)
228,
61-71[CrossRef][Medline]
[Order article via Infotrieve]
22.
Takazawa, K.,
Perret, J.,
DuMont, J. E.,
and Erneux, C.
(1991)
Biochem. Biophys. Res. Commun.
174,
529-535[CrossRef][Medline]
[Order article via Infotrieve]
23.
Takazawa, K.,
Perret, J.,
DuMont, J. E.,
and Erneux, C.
(1991)
Biochem. J.
278,
883-886
24.
Choi, K. Y.,
Kim, H. K.,
Lee, S. Y.,
Moon, K. H.,
Sim, S. S.,
Kim, J. W.,
Chung, H. K.,
and Rhee, S. G.
(1990)
Science
248,
64-66 25.
Takazawa, K.,
VanDekerckhove, J.,
DuMont, J. E.,
and Erneux, C.
(1990)
Biochem. J
272,
107-112[Medline]
[Order article via Infotrieve]
26.
Thomas, S.,
Brake, B.,
Luzio, J. P.,
Stanley, K.,
and Banting, G.
(1994)
Biochim. Biophys. Acta
1220,
219-22[Medline]
[Order article via Infotrieve]
27.
Clandinin, T.,
DeModena, J.,
and Sternberg, P.
(1998)
Cell
92,
523-533[CrossRef][Medline]
[Order article via Infotrieve]
28.
Takazawa, K.,
and Erneux, C.
(1991)
Biochem. J.
280,
125-129
29.
Communi, D.,
Takazawa, K.,
and Erneux, C.
(1993)
Biochem. J.
291,
811-816
30.
Togashi, S.,
Takazawa, K.,
Endo, T.,
Erneux, C.,
and Onaya, T.
(1997)
Biochem. J.
326,
221-225
31.
Hanahan, D.
(1985)
in
DNA Cloning: A Practical Approach
(Glover, D. M., ed)
, p. 109, IRL Press Ltd., Oxford
32.
Köhler, G.,
and Milstein, C.
(1975)
Nature
256,
495-49[CrossRef][Medline]
[Order article via Infotrieve]
33.
Sanger, F.,
Nicklen, S.,
and Coulson, A. R.
(1977)
Proc. Natl. Acad. Sci. U. S. A.
74,
5463-5467 34.
Kyhse-Andersen, J.
(1984)
J. Biochem. Biophys. Methods
10,
203-209[CrossRef][Medline]
[Order article via Infotrieve]
35.
Picard, V.,
Ersdal-Badju, E.,
Lu, A.,
and Bock, S. C.
(1994)
Nucleic Acids Res.
22,
2587-2591 36.
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
37.
Shell, M. J.,
Letcher, A. J.,
Brearley, C. A.,
Biber, J.,
Murer, H.,
and Irvine, R. F.
(1999)
FEBS Lett.
461,
169-172[CrossRef][Medline]
[Order article via Infotrieve]
38.
Saiardi, A.,
Erdjument-Bromage, H.,
Snowman, A. M.,
Tempst, P.,
and Snyder, S. H.
(1999)
Curr. Biol.
9,
1323-1326[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
G. W. Mayr, S. Windhorst, and K. Hillemeier Antiproliferative Plant and Synthetic Polyphenolics Are Specific Inhibitors of Vertebrate Inositol-1,4,5-trisphosphate 3-Kinases and Inositol Polyphosphate Multikinase J. Biol. Chem., April 8, 2005; 280(14): 13229 - 13240. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Nalaskowski, U. Bertsch, W. Fanick, M. C. Stockebrand, H. Schmale, and G. W. Mayr Rat Inositol 1,4,5-Trisphosphate 3-Kinase C Is Enzymatically Specialized for Basal Cellular Inositol Trisphosphate Phosphorylation and Shuttles Actively between Nucleus and Cytoplasm J. Biol. Chem., May 23, 2003; 278(22): 19765 - 19776. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-C. Chang, A. L. Miller, Y. Feng, S. R. Wente, and P. W. Majerus The Human Homolog of the Rat Inositol Phosphate Multikinase Is an Inositol 1,3,4,6-Tetrakisphosphate 5-Kinase J. Biol. Chem., November 8, 2002; 277(46): 43836 - 43843. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Saiardi, E. Nagata, H. R. Luo, A. Sawa, X. Luo, A. M. Snowman, and S. H. Snyder Mammalian inositol polyphosphate multikinase synthesizes inositol 1,4,5-trisphosphate and an inositol pyrophosphate PNAS, February 8, 2001; (2001) 41614598. [Abstract] [Full Text] |
||||
![]() |
A. Sai |